DigestRedComo funciona
Red
/
Empresas
Sa
No verificado

Savara Inc.

Sobre qué escribimos

BiotecnologíaEventosFarmacéuticaMedicina - VariosSalud

59 Comunicados de prensa

Ver todos los comunicados de prensa
02/12/2025
Biotecnología
Material médico sanitario
Salud
Farmacéutica
Medicina - Varios
Industria
Savara and PARI Granted a European Patent Covering the Drug-Device Combination of MOLBREEVI* Delivered Via the Proprietary eFlow® Nebulizer System
Fuente
Savara Inc.
Editor
Business Wire
1.00
0
20/11/2025
Biotecnología
Farmacéutica
Salud
Eventos
Web y redes sociales
Savara Announces Participation in Upcoming Investor Healthcare Conferences
Fuente
Savara Inc.
Editor
Business Wire
1.00
0
12/11/2025
Biotecnología
Sanidad
Farmacéutica
Salud
Mercado de valores
Savara Reports Third Quarter 2025 Financial Results and Provides Business Update
Fuente
Savara Inc.
Editor
Business Wire
1.00
0
03/11/2025
Biotecnología
Farmacéutica
Finanzas
Salud
Higiene alimentaria
Material médico sanitario
Asociaciones/Profesionales
Medicina - Varios
Eventos
Web y redes sociales
Savara Announces Participation in Upcoming Investor Healthcare Conferences
Fuente
Savara Inc.
Editor
Business Wire
1.00
0
31/10/2025
Biotecnología
Farmacéutica
Salud
Medicina - Varios
Finanzas
Savara Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Total Gross Proceeds of $149.5M
Fuente
Savara Inc.
Editor
Business Wire
1.00
0
30/10/2025
Comunicación
Salud
Medicina - Varios
Farmacéutica
Biotecnología
Acciones y Obligaciones
Savara Announces Pricing of $130.0 Million Public Offering of Common Stock and Pre-funded Warrants
Fuente
Savara Inc.
Editor
Business Wire
1.00
0
29/10/2025
Mercado de valores
Biotecnología
Farmacéutica
Salud
Medicina - Varios
Savara Announces Proposed Public Offering
Fuente
Savara Inc.
Editor
Business Wire
1.00
0
29/10/2025
Mercado laboral
Higiene alimentaria
Farmacéutica
Salud
Medicina - Varios
Savara announces $75M Royalty Funding Agreement with RTW to Support the Potential Launch of MOLBREEVI* in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
Fuente
Savara Inc.
Editor
Business Wire
1.00
0
17/10/2025
Biotecnología
Farmacéutica
Salud
Medicina - Varios
Mercado laboral
Savara Announces Chief Medical Officer (CMO) Transition
Fuente
Savara Inc.
Editor
Business Wire
1.00
0
02/10/2025
Biotecnología
Farmacéutica
Salud
Medicina - Varios
Ferias y Congresos
Eventos
Industria
Savara Announces Encore Presentations of Results From the Phase 3 IMPALA-2 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at CHEST 2025
Fuente
Savara Inc.
Editor
Business Wire
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0